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Immunogenicity studies of synthetic peptides from different regions of VP, protein of foot-and-mouth disease virus strain AZZ revealed the following 
active fragments: 39-61, 50-69, 135-159, 175-189, 170-189 and 197-213. Testing of virus neutralizing antibody production in rabbits primed by 
peptides and then inoculated by the virus showed that only peptides 135-159 and 176189 were able to induce the functional T-cell helper activity. 
Localization of virus-specific T-cell recognition sites in sequences 135-159 and 17&189 was confirmed in in vitro recognition experiments of the 
virus by peptide activated mice lymphocytes. 
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1. INTRODUCTION 
The creation of purely peptide foot-and-mouth dis- 
ease vaccine meets with a number of problems, starting 
with identification of virus specific B- and T-cell epi- 
topes. Over the past years considerable advances in B- 
epitope identification have been made [1,2]. The epi- 
topes recognized by T-cell so far attract less attention. 
Recently the 21-40 VP, fragment of foot-and-mouth 
disease virus (FMDV) 0,K strain was estimated as im- , . 
munodominant for vaccinated cattle [3]. However other 
T-epitopes can not be excluded from the VP, sequence, 
particularly bearing in mind that peptide from the C- 
terminal part of the protein showed pronounced T-cell 
stimulatory activity [3]. Moreover, VP, sequences from 
different FMDV strains might differ in the location of 
their T-epitopes. In the present study we identified new 
virus specific T-cell epitopes for VP, of FMDV strain 
ion-exchange chromatography. The yield of peptides was 60-70% 
_,_ 
(counting on the first amino acid). The homogeneity of peptides was 
higher than the negative standard. 
confirmed by amino acid analysis, mass-spectral data and by HPLC 
on a TSK-ODS column (4.6 x 250 mm) in acetonitril gradient in 0.05% 
TFA (from 0 to 70%). 
2.2. Immunization 
Animals were inoculated with peptides twice, with 44 days between 
immunizations. The inoculation dose was 200 pg for rabbits or 100 
pg for guinea pigs and mice. The dose of inactivated purified virus A,, 
[5] was 20 pg. CFA was used for the first injection and IFA was 
employed for the booster one. On the 55th day after the first inocula- 
tion samples of blood were obtained, and guinea pigs received 500 
half-infectious doses of As2 FMDV. The protection was tested on the 
5th day after the challenge [6]. Serum neutralizing activity was deter- 
mined in the pig kidney cell culture containing 100-320 ID,, of virus. 
TVA (in -log, scale) was calculated as serum dilution at which the 
50% tissue ciiopathic effect was depressed [6]. An indirect ELISA 
technique was used to assay the TPA (in -log,, scale). The plates 
(Costar, Cambridge) were coated with uncoupled peptides at concen- 
tration of 20 &ml. Antibody titers were calculated as serum dilution 
at which the Aao, value exceeded 0.1. the value being at least 2-times 
2. -EXPERIMENTAL 
2.1. Peptide synthesis 
Peptides were synthesized using solid-phase chemistry on the PAM- 
polymer [4]. Boc-derivatives of trifunctional amino acids were used as 
Thr(Bzl), Ser(Bzl), Glu(OBzl), Asp(OBzl), Tyr(BzlClJ, Arg(Tos), 
His(Bom), Cys(Acm), Lys(ZC1). The cleaved peptides were purified by 
*Corresponding author. Fax: (7) (095) 335 61 77; Telex 411982 
trem su. 
2.3. virus specificity of antipeptide T-helper response 
Rabbits were inoculated with free peptides (200 pg) with CFA, 28 
days later the animals received the inactivated purified virus A,, (5 pug) 
with IFA. On the 4th day after the virus injection the blood samples 
were obtained, TPA and TVA were measured. The T-cell proliferation 
was assayed as described [7]. Briefly, BALB/c mice were inoculated in 
the base of the tail and in the hind footpads (100 lug of peptide with 
CFA). After 7 days lymph node cells were obtained. Dilutions of 
peptides or inactivated purified virus A, were added to cells. After 
the incubation of cells (37”C, 5% COz, 90% H,O) for 3 days 1 PCi 
[Wlthymidine was added and pulsed cells harvested 18 h later. 
Abbreviations: PAM, 4-(oximethyl)phenylacetamidomethyl; TPA, 
titer of antipeptide antibodies; TVA, titer of virus neutralizing anti- 
bodies; CFA, complete Freund’s adjuvant; IFA, incomplete Freund’s 
adjuvant. 
3. RESULTS AND DISCUSSION 
The VP, (AZ2 strain) fragments elected for synthesis 
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Fig. 1. Synthetic peptides from VP, of the FMDV Azt strain. 
are shown in Fig. 1. The choice was based on standard 
theoretical predictions of antigenic determinants [8]. 
Data on VP1 variability were also taken into account [9]. 
Peptide IO-24 is hydrophilic and contains a B-bend. The 
39-61 peptide represents a highly variable VP, region; 
W-69 forms an amphipathic a-helix. Peptide 135-159 
from the main immunogenic site includes ‘Tyr136 resi- 
due’ exposed on the virion surface [lo], the variable 
136-144 region and an amphipathic a-helix. The 170- 
189 region is both conservative and hydrophilic. The 
peptide with the 170-l 89 VP, sequence was prepared in 
two forms: with the free SH-moiety of the Cys’*’ residue 
(170-189) and with Acm group on that moiety (170- 
189Acm). Peptide 197-213 was selected because of the 
known antigenicity of the 200-213 section [1 11; it in- 
cludes a hydrophilic 197-I 99 sequence. 
The antigenic properties of synthetic peptides were 
estimated from ELISA data of peptide binding with 
antivirus rabbit sera (Table I). Only peptides 135-159 
and 197-213 bind to the virus antibodies, the rest of the 
peptides being inactive in that test. These two fragments 
have been reported as the only virus-neu~alizing B- 
epitope containing sites [1,2]. 
Immunogenicity of synthetic peptides in different 
mice strains, rabbits and guinea pigs was studied (Table 
II). The results from Table II for peptides 10-24, 50-69, 
Table I 
Binding of rabbit antivirus serum to synthetic VP, fragments 
Peptide Titer of antivirus antibodies f-lg) 
lo- 24 < 1.0 
39- 61 < 1.0 
50- 69 <: 1.0 
9& 98 < 1.0 
175-189 < 1.0 
170-189 < 1.0 
197-213 1.6 
1355159 3.1 
135-159, 175-189 and 197-213 were partially described 
[12,13]. Judging from the antipeptide titers peptides 39- 
61,50-69, 135-159, 175-189, 170-189 and 197-213 are 
immunogenic. However, these peptides were unable to 
induce formation of the virus neutralizing antibodies in 
rabbits and in guinea pigs and to protect guinea pigs 
against the disease, the only exception being the earlier 
described protective peptide 135-l 59 from the main im- 
munogenic region [13]. Analysis of antipeptide titers 
showed that peptides 39-61, 135-l 59 and 170-189 were 
the most potent immunogens. Peptide 39-61 was able 
to induce a high level of peptide antibodies in mice 
BALBlc and CBA/J, rabbits and guinea pigs. Peptide 
135-l 59 was i~unogenic in mice. BALBlc, C57BL16, 
rabbits and guinea pigs. Fragment 170-l 89 induced for- 
mation of antibodies in all investigated animals with 
high titers. Peptide 197-213 was immunogenic only in 
rabbits and guinea pigs. Antibodies against his peptide 
were not virus neutralizing despite the presence of a 
minor virus neutralizing B-epitope in this VP, part [2]. 
We believe that antibody-inducing site of the free pep- 
tide 197-213 is not a virus-neutralizing B-epitope. 
Of the peptides studied, the fragments outside the 
main and the minor immunogenic sites did not contain 
virus-neutrali~ng B-epitopes. However, the immuno- 
genicity of these peptides indicates the presence of T- 
helper epitopes capable of stimulating the antipeptide 
T-cell immunity. In this work we studied the ability of 
the most potent immunogenic peptides 39-61, 135-l 59, 
Table II 
Immunogenicity of synthetic VP, fragments 
Peptide 
BALBlc 
TPA 
Mice 
CBA/J 
TPA 
C57BU6 
TPA 
Rabbits Guinea pigs 
TPA TVA TPA TVA Protection (%) 
lo- 24 < 1.0 < 1.0 < 1.0 < 1.0 < 1.0 < 1.0 c. 1.0 0 
39- 61 5.5 3.1 < 1.0 5.0 < 1.0 4.1 <: 1.0 0 
50- 69 c: 1.0 c 1.0 < 1.0 3.1 < 1.0 2.5 < 1.0 0 
9% 98 < 1.0 < 1.0 < 1.0 < 1.0 < 1.0 < 1.0 c: 1.0 0 
135-159 3.4 c 1.0 4.8 3.8 4.2 3.4 3.7 100 
175-189 2.6 3.2 2.8 4.9 < 1.0 c 1.0 <: 1.0 0 
170-189 5.8 5.8 5.5 5.2 < 1.0 4.1 < 1.0 0 
197-213 < 1.0 <: 1.0 < 1.0 3.5 < 1.0 2.8 c: 1.0 0 
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Table III 
Enhancement of virus-neutralizing antibodies by priming with syn- 
thetic peptides 
First 
immunization 
39- 61 
39- 61 
135-159 
135-159 
170-189 
170-189 
197-213 
197-213 
CFA 
Second 
immunization 
virus 
virus 
- 
virus 
- 
virus 
VirUS 
TPA TVA 
4.4 1.2 
4.4 < 1.0 
3.4 4.4 
3.4 1.5 
4.9 4.0 
4.9 < 1.0 
3.6 1.5 
3.6 < 1.0 
< 1.0 1.3 
170-189 and fragment 197-213 from the minor immu- 
nogenic site to activate the virus-specific T-helper cells 
and to induce antiviral T-cell i~unity. The rabbits 
were primed with different peptides, the second immu- 
nization was performed with a suboptimal dose of the 
inactivated and purified virus (Table III). Priming with 
CFA or inoculation with the peptides without second 
immunization with the virus was employed as a control. 
Among the fra~ents investigate only 135-159 and 
170-I 89 enhanced the virus neutralizing antibody for- 
mation. Immunization with peptide 135-I 59 alone in- 
duced virus-neutralizing antibodies (titer 1.5) that was 
due to the presence of virus-neutralizing B-epitope in 
the peptide. A significant increase in the virus-neutraliz- 
ing antibody titers after second inoculation with the 
virus (up to titer 4.4) were ascribed to recognition by the 
virus of B- and T-cells activated by peptide 135-l 59. 
Peptide 170-189 did not contain virus neutralizing B- 
epitopes and thus inoculation with that peptide did not 
stimulate the formation of neutralizing antibodies. 
However, priming with peptide 170-189 followed by 
inoculation with the virus induced neutralizing antibod- 
ies with titer 4.0. The virus was thus recognized by 
T-helper cells activated by the peptide. Peptides 39-61 
and 197-213 were unable to enhance the formation of 
the virus induced neutralizing antibodies. 
Specificity of peptide activated T-cells was investi- 
gated in vitro on BALB/c mouse lymphocytes (Table 
IV). Mice were immunized with peptides 39-61, 135 
159 and 170-189 (‘immunogens’ in Table IV), and 7 
days later the ability was tested of peptides 39-61, 135 
159, and 170-l 89Acm, control peptides 90-98 and 136 
152, and of the virus (‘antigens’ in Table IV) to induce 
the proliferative activity of lymphoid cells. Peptide 170- 
189Acm was employed in this case as an antigen be- 
cause we found out that the S-unprotected peptide 170- 
189 non-s~c~cally inhibits proliferation of lymphoid 
cells in vitro (data not shown). Uninoculated animals 
were employed as control. 
Peptides 135-I 59, 176189Acm, 39-61 were able to 
stimulate the proliferative activity of the cells from the 
animals inoculated with the same peptide. However, the 
virus was able to induce the T-cell proliferation only 
when mice were inoculated with peptides 135-159 or 
1’70-189. 
The above results prove that peptide 135-159 in- 
cludes not only the virus-neutralizing B-epitope, but 
also the virus-specific T-epitope. Peptide 170-189 does 
not contain the vies-neutrali~ng B-epitope, but in- 
cludes the virus-specific T-helper epitope. Taking into 
account that peptide 170-189 contains a conserved VP, 
region, we propose to apply this peptide as a T-cell 
carrier for FMDV protective B-epitopes in anti-FMD 
Table IV 
Virus induced proliferation of BALBfc mice lymphoid cells activated with the peptides 
Immunogen Antigen c.u.m. 
0 ,uM* 0.1 ,oM 1~lM 10,~M 100 PM 
39 61 
135-159 
170-189 
39- 61 17,542 I!z 3,037 20,039 f 1,942 24,290 + 796 31,408 + 2,758 
Virus** 17,542 + 3,037 16,247 + 2,958 16,175 k 1,015 18,785 Y!Z 3,351 
136-152 17,542 + 3,037 11,759 f 1,919 17,269 f 1,830 19,650 f 450 
135-159 5,635 + 704 6,152 k 1,283 14,422 f 2,529 30,401 + 2,799 
Virus** 5,635 + 784 4,990 f 1.56 9,132 k 130 12,382 + 667 
9% 98 5,635 f 784 5,540 * 700 5,340 + 758 5,308 + 209 
17@189Acm 6,231 rf 546 5,482 + 1,392 13,262 + 1,550 26,465 + 1,122 
Virus** 6,231 + 546 5,692 f 761 10,011 f 5,417 15,141 k 970 
136-152 6,231 + 546 5,443 f 698 5,915 f 161 7,388 1: 726 
135-159 2,787 f 625 2,391+ 137 2,659 + 262 2,867 + 255 
170-189Acm 2,787 k 625 2,543 f 115 2,548 k 338 2,508 zk 177 
39- 61 2,787 i 625 2,829 + 193 2,773 244 2 2,764 199 k 
Virus** 2,787 + 625 2,536 lr 216 2,271 124 + 2,334 245 I!Z 
*Peptide concentration. **Purified inactivated virus A, in concentrations: 0.05; 0.1; 1; 5 fig/ml. 
64,756 rt 6,747 
19,113 2,198 rt 
18,034 2,763 f 
41,245 5,375 t
18,280 + 1,823 
5,488 f: 248 
28,838 z!z 2,884 
18,149 rt 3,817 
6,571 1,469 + 
2,434 158 2 
2,505 29 + 
2,673 k 368 
2,817 + 688 
177 
syurthetic vaccines. Imcorporation of the 170-189 pep- 
tide into the synthetic construction will induce T-he&m 
memary c&s mx?~~ti by difkent semt~s d 
FMDV. 
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